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1. Introduction 
Breast cancer is the most commonly diagnosed malignancy within the female population of 
developed countries and is the first leading cause of cancer deaths in women. In the 
European Union (EU27) every year there are an estimated 319.000 new cases diagnosed, and 
approximately 131.000 deaths, which comprises 16.7% of all cancer caused deaths in women 
(Ferlay et al., 2007). 
The causes of breast cancer are not fully understood, but the epidemiology of the disease 
clearly shows that hormonal factors play a key role. Estrogen production appears as one 
potential risk factor among women worldwide because it stimulates the proliferation of 
breast epithelial cells (Ekbom et al., 1997; Ferlay et al., 2007). Coincident with this 
proliferation, breast cancer risk increases in early menarche, late menopause and with 
obesity in postmenopausal women (situations where there is a direct association between 
estrogen and breast cancer risk). In general, breast cancer risk decreases around 5% with 
each year that menarche is delayed. Breast cancer incidence rates also increase more slowly 
after menopause; therefore a woman with a natural menopause at age 45 years has half the 
risk of developing this type of cancer that a woman with menopause at age 55 (Kelsey et al., 
1993; Key et al., 2001).  
Childbearing seems to have a dual effect on risk of breast cancer (Key et al., 2001). On one 
hand the immediate effect is to temporarily increase the risk after a birth, yet on the other, 
this risk diminishes in the long term and the overall effect of a pregnancy is to reduce the 
overall risk of developing this disease. It appears that the negative short term effect is due to 
the increase in estradiol levels in early pregnancy. However, has been seen that 
premenopausal parous women have lower global levels of circulating estradiol than in 
nulliparous premenopausal women. This effect is observed among postmenopausal women, 
suggesting that this diminution is stable (Ewertz et al., 1990). Women who have had at least 
one child have around a 25% reduction in breast cancer risk compared to nulliparous 
women (Layde et al., 1989; Ewertz et al., 1990).  
Moreover, the use of menopausal hormonal therapy increases the risk of breast cancer; in 
fact, the use of these estrogen preparations over a period of 10 years, increases cancer risk by 
35%(Key et al., 2001). Other risk factor associated with breast cancer is family history and 
genetic predisposition. Women with a first-degree relative have about a two-fold risk of 
www.intechopen.com
 Breast Cancer – Carcinogenesis, Cell Growth and Signalling Pathways 
 
222 
developing breast cancer. However the risk is lower when only second-degree relatives are 
affected (Pharoah et al., 1997). Several germline mutations that have a prediposition for the 
development of breast cancer have been identified: BRCA1, BRCA2, P53, PTEN, ATM, 
NBS1, RAD50, BRIP1, PALB2 and CHEK2 (Walsh and King, 2007). In addition, the 
International Agency for Research on Cancer (IARC) estimates that 25% of all cancers are 
associated with overweight and obesity. This increase in cancer risk is approximately linear 
with increasing body-mass index, yet is reduced in the more physically active, equivalent 
population (McTiernan, 2003). In the European Union, 13.000 cases of breast cancer could be 
avoided annually by maintaining a normal body weight (Devenish et al., 1979). The 
increased risk in obese postmenopausal women may be due to higher levels of circulating 
estrogens (Lahmann et al., 2004). For many years this risk has been linked to higher 
estrogenic synthesis by the aromatase process in the adipose tissue and recent studies 
showed that the hormones secreted for this tissue have the capacity to induce tumour cell 
proliferation and survival (Catalano et al., 2003; Lahmann et al., 2004; Garofalo and 
Surmacz, 2006). 
The most common type of breast cancer is invasive ductal carcinoma (IDC), and about 80% 
of all breast cancers are of this histological type. The second most common type is invasive 
lobular carcinoma (ILC), represents approximately 10%. Tubular carcinoma of the breast is a 
rare subtype of invasive ductal carcinoma, and accounts for only 1-2% of all breast cancer 
cases (Novelli et al., 2008). 
2. Estrogen receptors 
2.1 History of estrogen 
Estrogen is term derived from Greek oistros¸ a word which refers to oestrus, the phase in 
which females are sexually receptive. In women with active menstrual cycles, daily ovary 
estrogen production is between 70 and 500 micrograms, with 17ǃ-estradiol (E2) the most 
important one. Studies report that the production E2 of increases under the influence of 
gonadotropins secreted by the pituitary gland and by the maturation of ovarian follicles. 
Follicular estrogens induce the growth and development of female sex organs and to 
maintain sexual characteristics, as well as influence female behaviour (Morani et al., 2008). 
Studies of action of E2 on the uterus, directed by Jensen, led to the conclusion that the 
biological effects of estrogen occur through the activation of estrogen receptor (ER) (Jensen 
et al., 1972). In the classical scheme of reproductive organ development, estrogens were 
considered as “female hormones”, while testosterone was thought to be the “male 
hormone”. In the 1980’s the studies began to analyse effects of estrogen in non-target organs 
for the action of this hormone, i.e. in organs that are not associated with reproduction. The 
importance of estrogens in the bone homeostasis was recognised because of the observed 
increased risk of osteoporosis in postmenopausal women. However, it was a publication in 
1994 of a case report of male with an ER mutation who had abnormal bone density and 
impaired glucose tolerance that finally confirmed the importance of estrogens in both males 
and females (Smith et al., 1994). 
It was only until 1985, 23 years after the discovery of ER by Jensen, that this receptor was 
identified as a member of nuclear receptor superfamily (Greene et al., 1980; Walter et al., 
1985; Green et al., 1986). Ten years later, in 1995, Gustafsson’s laboratory discovered a 
second ER. The “Jensen” receptor was than named ERǂ and the new receptor ERǃ (Kuiper 
et al., 1996). ERǂ and ERǃ have distinct tissue expression patterns (Kuiper et al., 1997). In 
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fact, many tissues previously thought to be “estrogen-insensitive tissue” were found to be 
ERǃ positive and estrogen sensitive, with ERǃ highly expressed and is almost the exclusive 
ER in ovarian granulose cells. ERǂ is the main ER subtype in the liver, breast and ovaries, 
while ERǃ is predominantly in the prostate, colon and lung (Gustafsson, 1999; Pearce and 
Jordan, 2004). Thus, the proliferative actions of estrogens mediated via ERǂ can be opposed 
by ERǃ (Pearce and Jordan, 2004; Chang et al., 2008; Jensen et al., 2010). 
2.2 Estrogen receptors structure 
ERǂ and ERǃ have the typical structure of the nuclear receptor family (figure 1): a highly 
variable N-terminal region (A/B domain, involved in protein-protein interactions with 
transcriptional machinery and cofactors), a highly conserved DNA-binding domain (C), a 
hinge domain (D), a ligand-binding domain (E) and a C-terminal domain (F) (Giguere et al., 
1986; Kumar et al., 1987). 
 
 
Fig. 1. ERǂ and ERǃ structures. Schematic representation of the structure ERǂ and ERǃ, 
structure DNA binding domain and structure of the hormone binding domain of both 
estrogen receptors.  
ERǂ (595 aa) and ERǃ (530 aa) receptors are codified by two different genes with less than 
18% homology between them in A/B domain, although there is a 97% of homology between 
their respective DNA-binding domains (the most conserved). This domain (C) contains two 
zinc fingers and has a short motif, called a P-box, which is responsible for DNA specificity 
and is also involved in dimerization (Nilsson et al., 2001; Morani et al., 2008). Consequently 
both receptors ERǂ and ERǃ bind to DNA in a similar manner, but the association with 
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different cofactors enables them to modulate transcription genes (Giguere et al., 1986; 
Kumar et al., 1987). The D domain has nuclear localization signals and could provide 
malleability between the C and E domains. The E domain has the property for ligand 
binding, with its ligand-binding pocket formed by 12 alpha-helixes, and which is 60% 
conserved between the two estrogen receptors (Spithill et al., 1979; Morani et al., 2008). 
Moreover this domain is also involved in other functions such as receptor dimerization, 
nuclear localization and cofactor interaction. Finally, the F domain is extremely variable and 
contributes gene transactivation capacity (Morani et al., 2008).  
2.3 Mechanisms of ER activation 
Estrogens can act through different mechanisms and pathways to cause their biological 
effects (Gonzalez et al., 1993; Nilsson et al., 2001). There is a typical nuclear receptor 
superfamily mechanism to modulate the expression of several genes. Estrogen activates ER 
by ligand binding to the receptor, but this unity can occur in to forms. The first can occur 
when E2-ER complex has formed in the cytoplasm and then is transported to the nucleus 
through cytoskeleton regulated mechanisms. The second form has the same final product, 
but occurs by a direct E2 binding to the ER in the nucleus, with this union allowing for 
eventual ER dissociation of the chaperon proteins and the restoration of the ER to the 
inactive state. After this dissociation, ER can form either heterodimers or homodimers and 
bind directly to estrogen response element (ERE) through the DNA-binding domain as well 
as by association with different gene regulation co activators (Nilsson et al., 2001; Morani et 
al., 2008).  
Another mechanism includes the involvement of the SP1 protein in the formation of the 
bridge between the activated estrogen receptor dimer and ERE (Kushner et al., 2000; Saville 
et al., 2000). This mechanism forms an indirect activation/inhibition of E2 regulated genes 
and some authors have found differences dependant on the ERǂ and ERǃ union to ERE 
(Sidhu and Tauro, 1979; Morani et al., 2008).  
Another action of ERs, in a non-genomic process, involves the interaction of activated ERs 
with secondary messenger proteins (SM) with rapid, concomitant effects in many tissues, 
although this process is still not well understood (Heldring et al., 2007). 
Furthermore, ERs have a ligand-independent activation mechanism, involving kinases that 
phosphorylate and activate ERs and this mechanism could explain the hormone-
independent growth of some tumours. 
Other factors have an important role in the activation mechanisms of ERs and serve as 
corregulators (or cofactors) recruited by the ERs to activate (coactivator) or to repress 
(corepressor) the transcriptional activity of ERs. These corregulators can modify the affinity 
of the ERs to EREs and can be in the form of acetylases/deacetylases, kinases/phosphatases 
and methylases/demethylases. It must be emphasized, however, that the pool of 
corregulators can differ according to the type of tissue, and it is the fact that has been 
proposed as an explanation for the differential tissue effects of estrogen and selective 
estrogen receptor modulator (SERMS). 
Moreover, not only do corregulators differ according to tissue, the distribution of ERǂ and 
ERǃ has also been reported to vary. In the tissues when both ERǂ and ERǃ coexist, their 
effects seem to counteract each other. Thus, in the uterus, mammary glands and the immune 
systems, ERǂ promotes cell proliferation while ERǃ has proapoptotic and cell differentiation 
functions (Morani et al., 2008).  
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Fig. 2. Mechanisms ER activation. 
3. Breast cancer and estrogens 
3.1 Mammary gland and estrogens 
Development and physiology of the mammary gland are under estrogen control and suffers 
important changes during a women’s lifespan and estrogens have an active role in these 
changes. During puberty the glands undergoes an increased cellular division and in adult 
life there is a proliferation/involution cycle according to menstrual cycle (Russo et al., 1999).  
The role of estrogen in mammary epithelial proliferation has been unclear, because the 
proliferation markers in ductal epithelial cells never co localize with ERǂ (Saji et al., 2000).  
For a long time, estrogens were believed to induce proliferation through indirect effects, 
such as growth factor secretion to the stroma. However, recent studies suggest that when 
ERǂ is activated by estrogen it is quickly lost in the beginning of the G1 phase of the cell 
cycle. This fact could be explain the non-colocalisation of ERǂ with proliferation markers, 
such as cyclin A or PCNA, tipycal from the S phase (Morani et al., 2008).  
Ductal cells in the mammary gland appear to be one example of cells where ERǂ and ERǃ 
counteract each other in estrogen-stimulated proliferation. The proliferative response to E2 
seems to be determined by the ratio of ERǂ ⁄ ERǃ. The functions of ERǃ in the breast are 
probably related to its antiproliferative as well as its prodifferentiative functions (Strom et 
al., 2004). 
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In studies with MCF7 cells, a breast cancer cell line expressing ERǂ but not ERǃ, showed 
that E2 increases proliferation, and when ERǃ was artificially introduced into these cells, E2-
induced proliferation was inhibited (Schatz, 1979). 
3.2 Breast cancer estrogen induction 
Estrogens are a major risk factor for breast cancer initiation and progression, as they affect 
epithelial mammary cell growth and these cells are more susceptible to make DNA 
replication errors. Another point of view is that estrogens produce oxidant species for their 
metabolism (quinine metabolites) that can form adducts in DNA and generate reactive 
oxygen species (ROS) through a redox cycle (Russo et al., 2003; Yager and Davidson, 2006).  
 
 
Fig. 3. Estrogen carcinogenesis mechanisms: E2: 17ǃ-estradiol. ER: estrogen receptor. 16ǂ-
OH-E2: 16ǂ-hydroxyE2. 2-OH-E2: 2-hydroxyE2. 4-OH-E2: 4-hydroxyE2. 2-OH-E1 2-
hydroxyestrone. 4-OH-E1 4-hydroxyestrone.  
In recent years, EREs have been found in mitochondrial DNA, suggesting that the 
carcinogenic role of estrogen could be mediated by the action of these molecules in the 
mitochondria (Gonzalez et al., 1993; Sogl et al., 2000). Moreover, as mentioned earlier, the 
two subtypes of estrogen receptors have different actions in several tissues and therefore it 
is entirely possible that the effects will differ in mitochondria as well. Other papers have 
studied the localization of ERǂ and ERǃ in the mitochondria and the regulation of 
mitochondrial genes (Gonzalez et al., 1993; Sogl et al., 2000; Chen et al., 2004; Pedram et al., 
2006; Amutha et al., 2009; Usmanova et al., 2011). Furthermore, apoptotic pathways and the 
presence of estrogen receptor in the mitochondria could be important for carcinogenic 
processes (Gonzalez et al., 1993; Sogl et al., 2000). 
The majority of ER-positive breast tumours contain both ERǂ and ERǃ subtypes, although 
some tumours have only ERǃ and may have distinct clinical behaviours and responses. In 
contrast to ERǂ, studies suggest that ERǃ expression declines during breast tumourigenesis 
(Roger et al., 2001; Skliris et al., 2003; Bardin et al., 2004; Hartman et al., 2009). The 
mechanism by which ERǃ is downregulated is not fully understood, but epigenetic changes 
could play an important role (Zhao et al., 2003). This downregulation of ERǃ in breast 
cancers indicates a role for ERǃ as a tumour suppressor (Novelli et al., 2008; Fox et al., 2008). 
Characterization of the role of ERǃ in ERǂ negative tumors is basically unexplored, but 
available data suggest that the role of ERǃ may differ depending if it is co-expressed with 
ERǂ or expressed alone (Fox et al., 2008; Skliris et al., 2008; Hartman et al., 2009). Classically, 
the ERǂ negative tumors are considered endocrine resistant since they lack a receptor to 
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mediate the estrogenic response. However, it has been observed that approximately 50% of 
this subgroup expresses ERǃ (Skliris et al., 2006). Several studies have been published 
different conclusions for correlations with ERǃ, prognostic markers and clinical outcome. 
Reports have shown that tumours that co-expressed ERǃ and ERǂ have a good prognosis 
and good clinical outcome with adjuvant therapy. Additional studies have considered the 
addition of ERǃ to ERǂ as clinical tumor marker as beneficial (Murphy and Watson, 2006; 
Skliris et al., 2006; Gruvberger-Saal et al., 2007; Skliris et al., 2008; Hartman et al., 2009). 
Conversely, very few studies have focused on ERǃ expression in ERǂ negative breast 
tumors; where ERǃ has been described as a marker for poor prognosis and endocrine 
resistance (Leygue et al., 1998; Speirs et al., 1999; O'Neill et al., 2004; Skliris et al., 2006; Fox et 
al., 2008; Skliris et al., 2008; Hartman et al., 2009) (table 1). 
 
ERǂ and ERǃ status Clinical outcome 
ERǂ+/ ERǃ+ Increased overall survival and disease-free survival correlated ERǃ+ 
ERǂ+/ ERǃ- Worst prognosis  
ERǂ-/ ERǃ+ Less favorable prognosis, ERǃ seems to correlate with the proliferation 
Table 1. Clinical correlation between ERǂ/ ERǃ expression and evaluation response to 
endocrine therapy in breast cancer. 
An increased ERǂ/ERǃ ratio respect to non tumoral breast tissue is an important factor for 
the development of the cancerous phenotype (Stossi et al., 2004; Strom et al., 2004; Adam et 
al., 2006; Garcia-Roves et al., 2007; Morani et al., 2008). On the contrary, a decrease in this 
ratio (due to ERǃ increase) is indicative of a poor prognosis and problems with antiestrogen 
treatment (Power and Thompson, 2003). This evidence could also explain the different 
action of estrogens and phytoestrogens through varing ERǂ and ERǃ levels (Sotoca et al., 
2008).  
Another difference between ERǂ and ERǃ is estrogen activation, because estrogen 
stimulates both ERǂ and ERǃ receptors, although it is 10 times more selective for ERǂ than 
ERǃ (Kuiper et al., 1998; Quaedackers et al., 2001). Furthermore, several authors shave 
shown that estrogen regulation of ERǂ and ERǃ expression, causing a decrease in ERǂ and 
an increase in ERǃ in ERǂ-positive cell lines such as MCF-7 and T47D (Power and 
Thompson, 2003; Lee et al., 2005). In addition to this important fact, oxidative stress also 
regulates ERǂ and ERǃ levels, and in the same manner, causes downregulation of ERǂ and 
upregulation of ERǃ (Tamir et al., 2002). 
4. Estrogens, mitochondria and oxidative stress 
Classically, it has been suggested that estrogens induce growth in mammary gland 
epithelial cells. This high cell proliferation can increase susceptibility to the acquirement of 
error-induced mutations during DNA replication, which if not corrected can establish a 
malignant phenotype (Gonzalez et al., 1993). Another mechanism to explain this association 
is that estrogens can produce genotoxic metabolites during their metabolism (cathecol 
estrogens), that can make DNA adducts and create ROS through redox cycle (Russo et al., 
2003; Yager and Davidson, 2006), but for these compounds to have a relevant impact, the 
estrogen concentration must be higher than physiological levels. 
Recently, ERs have been found in the mitochondria, and in mitochondrial DNA there are 
EREs. Moreover, mitochondrial biogenesis and ROS production are under estrogen 
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influence. For this reason, some authors give estrogens a new role in the carcinogenesis 
process, in the modulation of mitochondrial function (Addison and McCormick, 1978; Sogl 
et al., 2000). The changes in mitochondrial function cause an increase in ROS production, 
which alters the control that mitochondria exerts in cellular proliferation and apoptosis, and 
which could explain the action of estrogen in cancer development (Addison and 
McCormick, 1978; Gonzalez et al., 1993). 
4.1 Mitochondria  
Mitochondria are important organelles in eukaryotic cells. The structure of the 
mitochondrion is delimited by an outer and inner membrane. The former is wrinkled and 
completely surrounds the organelle. The later has infolding called cristae where the 
mitochondrial respiratory chain (MRC) resides. The inner compartment of mitochondria, the 
matrix, is a concentrated aqueous solution of many enzymes and chemical intermediates 
involved in energy-yielding metabolism. The outer membrane is a relatively simple 
phospholipid bilayer, containing protein structures called porins which render it permeable 
to molecules of about 10 kDA or less (the size of the smallest proteins). Ions, nutrient 
molecules, ATP, ADP, etc. can pass through the outer membrane with ease. The inner 
membrane is only freely permeable to oxygen, carbon dioxide, and water. Its structure is 
highly complex, including all of the complexes of the electron transport system, the ATP 
synthase complex and transport proteins. 
 
 
Fig. 4. Mitochondrial structure. 
Mitochondria are the intracellular organelles responsible for the supply of ATP (generation 
of more than 90% of the cell’s energy requirements) and are also the main intracellular 
source and target of reactive oxygen species (ROS). Mitochondria also participate in the 
regulation of intracellular calcium homeostasis by controlling various ion channels and 
transporters and participation in heme and steroid biosynthesis. In addition, mitochondria 
play a role in the regulation of cellular proliferation and apoptosis (Gonzalez et al., 1993). 
The primary role of mitochondria is the generation of ATP through a complex process of 
controlled substrate degradation and oxygen consumption known as oxidative 
phosphorylation (OXPHOS) (Korb and Neupert, 1978). The inner membrane mitochondrial 
contains the large protein complexes that are necessary for energy transduction and ATP 
synthesis. Briefly, oxidation of reduced nutrient molecules, such as carbohydrates, lipids, 
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and proteins, through cellular metabolism yields electrons in the form of the reduced 
hydrogen carriers NADH+ and FADH2. These reduced cofactors donate electrons to a series 
of protein complexes of the electron transport chain embedded in the inner mitochondrial 
membrane. These complexes (complex I, III and IV) use the energy released from electron 
transport for the active pumping of protons across the inner membrane, thereby generating 
an electrochemical gradient. The ultimate destiny of these electrons is the reduction of 
molecular oxygen at complex IV to yield a molecule of water, whereas the energy, 
conserved as a proton gradient, is used by the F0F1 ATP synthase (or complex V) to 
phosphorylate ADP through the return of protons into the mitochondrial matrix (Devenish 
et al., 1978). 
 
 
Fig. 5. The mitochondrial oxidative phosphorylation system. 
Although mitochondria have their own genome, most of the proteins and enzymes that 
reside in the mitochondrial membranes are nuclear gene products. Each mammalian cell 
contains several hundred to more than a thousand mitochondria, and each organelle 
harbours 2–10 copies of mitochondrial DNA (mtDNA) (Amutha et al., 2008). The double-
strand circular mtDNA consists of 16,500 base pairs (bp). This DNA encodes 13 protein 
coding genes (or polypeptides), 22 transfer RNA (or tRNA) and 2 ribosomal RNA (or rRNA) 
necessary for the translation. The 13 polypeptides including seven subunits of complex I-
NADH dehydrogenase (ND1, ND2, ND3, ND4, ND4L, ND5, and ND6), three subunits of 
complex III-cytochrome c oxidase (COI, COII, and COIII), two subunits of complex V-
F0F1ATPase (ATPase 6 and ATPase 8), and cytochrome b are encoded by mtDNA and 
synthesized in the organelle (Molina-Navarro et al., 2006). A single major noncoding region, 
referred to as the displacement loop (D-loop), contains the primary regulatory sequences for 
transcription and imitation of replication (Menassa et al., 1997). mtDNA is first transcribed 
to a larger mitochondrial transcript precursor, from which the 13 mRNAs, 22 tRNAs and 2 
rRNAs are derived (Menassa et al., 1997). 
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Fig. 6. The mitochondrial genome. The mammalian mitochondrial genome is a circular 
double stranded molecule, composed of one heavy and one light strand. 
The assembly and functioning of the respiratory enzyme complexes in mammalian cells 
require coordinated expression and interaction between gene products of the mitochondrial 
and nuclear genomes (Menassa et al., 1997). Correct mitochondrial biogenesis relies on the 
spatiotemporally coordinated synthesis and import of ~1000 proteins encoded by the 
nuclear genome, of which some are assembled with proteins encoded by mitochondrial 
DNA within the newly synthesized phospholipid membranes of the inner and outer 
mitochondrial membranes. (Klingenspor et al., 1996). 
 
 Complex I Complex II Complex III Complex IV Complex V 
mtDNA 7 0 1 3 2 
nDNA 39 4 9 10 10 
Table 2. Nuclear and mitochondrial respiratory subunits. 
Transcription and replication of mitochondrial DNA is driven by the nuclear-encoded 
mitochondrial transcription factor A (TFAM), which binds to a common upstream enhancer 
of the promoter sites of the two mitochondrial DNA strands. (Klingenspor et al., 1996) 
Additionally, two proteins that interact with the mammalian mitochondrial RNA 
polymerase and TFAM, TFB1M and TFB2M, can support promoter-specific mtDNA 
transcription (Addya et al., 1997). Nuclear respiratory factors 1 and 2 control (NRF1 and 
NRF2) play an important role in the regulation of mitochondrial respiratory function, as 
they on one hand control nuclear transcription of the subunits of the respiratory chain 
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complexes (Schuster, 1994) as well as activate the expression of factors involved in the 
initiation of transcription of the mitochondrial genome, such as TFAM, and TFB2M TFB1M 
(Addya et al., 1997). 
 
 
Fig. 7. Coordination of transcription of nuclear and mitochondrial genes encoding OXPHOS 
by steroid hormones. 
The TFAM promoter contains recognition sites for NRF1 and/or NRF2, thus allowing 
coordination between mitochondrial and nuclear activation during mitochondrial 
biogenesis. However, there is a subset of genes that does not appear to be regulated by 
NRFs. For example, fatty acid transport proteins and oxidation enzyme genes are mainly 
regulated by the peroxisome proliferator-activated receptor alpha PPARǂ (Klingenspor et 
al., 1996). 
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Peroxisome proliferator-activated receptor gamma co-activator (PGC-1ǂ) lacks DNA-binding 
activity but interacts with and co-activates numerous transcription factors including NRFs on 
the promoter of TFAM. Mitochondrial biogenesis and respiration are stimulated by PGC-1ǂ 
through a powerful induction of NRF1 and NRF2 gene expression (Giege et al., 2008). Data are 
accumulating that show PGC-1ǂ to be a master regulator of mitochondrial biogenesis in 
mammals (Klingenspor et al., 1996). In addition to NRFs, PGC-1ǂ also interacts with and co-
activates other transcription factors like PPARs, thyroid hormone, glucocorticoid, estrogen, 
and estrogen-related ERRǂ and Ǆ receptors (Klingenspor et al., 1996). 
4.2 Estrogen and mitochondrial biogenesis 
The synthesis of thirteen polypeptides within mitochondria are under the regulation of 
hormones and other factors, including cortisol, androgen, glucocorticoids, 1,25ǂ-
dihydroxyvitamin D3, thyroid hormone, estrogens and peroxisome proliferators, which 
have profound effects on mitochondrial respiratory chain (MRC) activities (Gonzalez et al., 
1993; Sogl et al., 2000). Thus, receptors for glucocorticoids, thyroid hormone, estrogens and 
androgens have been detected in mitochondrial and specific steroid hormone responsive 
elements for glucocorticoids, thyroid hormone and estrogen are found in the human 
mtDNA regulatory region. Moreover the ligand-activated glucocorticoid receptor, a variant 
form of the thyroid hormone receptor and a 45 kDa protein related to peroxisome 
proliferation-activated receptor Ǆ2, have each been shown to mediate stimulatory effects on 
mitochondrial gene expression. In addition, these hormones and their receptors control a 
number of cellular processes including apoptosis and cell proliferation. It is likely that 
hormonal regulation of mitochondrial gene transcription occur through mechanisms similar 
to those that control nuclear gene transcription. These insights have extended our 
understanding of hormone action at the cellular level (Gonzalez et al., 1993). 
In the last years, there has been increasing evidence pointing to the MRC as a novel and 
important target for the actions of E2 and ERs in a number of cell types and tissues that have 
high demand for mitochondrial energy metabolism for their biological activities. This novel 
E2-mediated mitochondrial pathway involves the cooperation of the nuclear ERǂ and ERǃ 
with mitochondrial localized ERs and their co-activators on the coordinate regulation of 
both-encoded genes and mtDNA-encoded genes for MRC proteins (Sogl et al., 2000). 
ERǂ and ERǃ have been detected in the mitochondria of several human cells, including 
breast cancer cells such as MCF7 (Chen et al., 2004; Pedram et al., 2006). Thus estrogens 
regulate the biogenesis and mitochondrial function through cross-talk between the nucleus 
and the mitochondria to control the estrogen-induced signaling involved in the 
proliferation, apoptosis and differentiation cellular (Felty and Roy, 2005). E2 stimulates the 
expression of TFAM and possibly TFB1M and TFB2M via the activation of NRF-1 and NRF-
2, and it is likely that E2 and ERs stimulate the transcription via activation of the expression 
of these mitochondrial transcriptional factors (Sogl et al., 2000). Moreover, it has been found 
that E2 significantly enhanced the amounts of mitochondrial ERǂ and ERǃ in a time- and 
concentration-dependent manner and that these effects are accompanied by a significant 
increase in the transcript levels of mtDNA-encoded genes (Chen et al., 2004). 
4.3 Estrogen and mitochondrial ROS production 
Mitochondrial ROS production is under estrogen influence and the consequences of this 
production in the control that mitochondria exerts in cellular proliferation and apoptosis 
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could be explain the action of estrogen in cancer development (Gonzalez et al., 1993; Sogl et 
al., 2000).  
Mitochondria are the most important source of ROS production in mammalian cells, as 
under normal physiological conditions about 1% of electrons during transfer along the 
respiratory chain, escape and form a single electron reduction of molecular oxygen to form a 
superoxide anion (O2-), which in turn is the precursor of other ROS (Fariss et al., 2005; 
Murphy, 2009). Aerobic respiration involves the complete reduction of oxygen to water, 
which is catalyzed by complex IV (or cytochrome c oxidase). Superoxide is rapidly 
converted to hydrogen peroxide (H2O2), either spontaneously or is enzymatically catalyzed 
by superoxide dismutase (SOD). H2O2, although not an oxygen free radical, can lead to the 
production, in the presence of ferrous iron via the Fenton reaction, of the highly reactive 
hydroxyl radical (OH). ROS production can be significantly enhanced with a high 
mitochondrial potential membrane that can occur with abundant fuel supply (high NADH 
production) or with the functional impairment of complexes I or III of respiratory chain, 
while ROS production decreased with reduced energy demand (Lenaz, 2001; Chen et al., 
2003; Fariss et al., 2005). 
 
 
Fig. 8. ROS detoxification mechanisms. 
ROS can be dissipated by the action of several enzymes, as SOD, glutation peroxidase (GPx) 
and glutation reductase (GR). SOD transforms O2- in H2O2, which is detoxified by the 
action of two enzymes, catalase and GPx yielding H2O. Glutathione (GSH) is regenerated 
from glutathione disulfide (GSSG) by the action of GR, using NADPH as a reducing 
equivalent. Non-enzymatic antioxidants (as vitamins C and E) provide alternative targets to 
ROS reactivity, thus avoiding the deleterious effects on cell components (Fariss et al., 2005; 
Murphy, 2009).  
Another mechanism to be included within the systems that can protect against oxidative 
damage are the uncoupling proteins or UCPs (Addison and McCormick, 1978; Echtay, 2007). 
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UCPs are a family of inner mitochondrial membrane proteins whose function is to allow the 
re-entry of protons into the mitochondrial matrix dissipate the proton gradient and, 
subsequently, decrease the membrane potential and ROS production (Addison and 
McCormick, 1978; Echtay, 2007). 
 
 
Fig. 9. Mitochondrial oxidative phosphorylation system and uncoupling protein. 
When cellular production of ROS overwhelms the overall antioxidant defenses, free radicals 
may escape and exert their deleterious effects. This situation is oxidative stress, and is 
supposed to be responsible for the accrual of cellular damage during its lifetime, thereby 
playing a role in the etiogenesis and course of numerous pathologies and in the aging 
process (Addison and McCormick, 1978; Lenaz, 2001). Macromolecules within the 
mitochondria are more prone to ROS-induced damage due to their physical proximity to 
ROS sources. In addition, mitochondrial DNA, which lacks protective histone shields and 
also has limited DNA-repair systems, is especially vulnerable to such damage. It is worth 
noting that the damage exerted by ROS on mitochondrial DNA may lead to a higher degree 
of mitochondrial dysfunction and in turn, to a higher ROS production, leading to a vicious 
cycle of ROS amplification (Fariss et al., 2005).  
Nevertheless, ROS should not be seen only in a negative light or as just damaging to 
molecules. It is worth noting that the rapidly-produced, short-lived, and highly diffusible 
ROS also perfectly fits the characteristics of a second messenger molecule. In fact, although 
ROS do cause damage, low levels of ROS are thought to participate in cell signaling 
processes such as cell proliferation, inflammation, apoptosis and phagocytosis (Obbink et 
al., 1977). Thus, it is well established by many studies that ROS may act as second 
messengers in cellular signaling transduction cascade pathways, including stress-activated 
protein kinases (SAPK) with both p38MAPK and c-Jun N-terminal kinase (JNK), p53 
(universal sensor of genotoxic stress) through PI3K/PKB and NF-κΒ pathways (Harkness et 
al., 1994; Sauer et al., 2001; Martindale and Holbrook, 2002; Sanders et al., 2004; Murphy, 
2009). In this complex context, low levels of ROS stimulate cellular proliferation, while high 
levels induce apoptosis. In summary, many cellular signal pathways are sensible to ROS 
levels and the final cellular response depends on the final cell interpretation, which is the 
result of equilibrium between apoptotic signals and proliferative and survival signals 
(Addison and McCormick, 1978). 
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Fig. 10. Mitochondrial DNA and oxidative stress and apoptosis.  
Estrogens can mediate in the complex process of ROS cellular level control. Thus, estrogens 
control mitochondrial biogenesis and maintenance, which are induced by signal pathways 
related to cellular proliferation, differentiation and apoptosis (Gonzalez et al., 1993). 
Moreover, mitochondrial ROS production can be regulated by estrogens through both 
nuclear and mitochondrial ER, with regulation by these via mitochondrial structure and 
function (Vic et al., 1982; Tam and Wong, 1991). Additionally estrogen controls the ROS 
dissipation, since expression of antioxidant enzymes and UCPs are induced by ERE (Chen et 
al., 2004). However, the literature is contradictory in this aspect, as the effect depends on 
tissue studied, estrogen concentration and in vitro or in vivo studies. For example, while 
oxidative stress induction in breast and prostate cancer cell lines has been described, in liver, 
brain, skeletal and cardiac muscle as well as adipose tissue, a protector role has been 
described to estrogen for the avoidance of oxidative stress (Valle et al., 2005; Colom et al., 
2007a; Colom et al., 2007b; Valle et al., 2007a; Valle et al., 2007b; Guevara et al., 2008; Valle et 
al., 2008). This controversy could be attributed to the different ERǂ and ERǃ ratios in 
different tissues. Thus in MCF7 breast cancer cell lines (with a high ratio of ERǂ/ERǃ) 
estrogen induces oxidative stress either by or in combination with mitochondrial 
dysfunction, decrease in antioxidant enzymes and/or UCPs. On the contrary, in MDA-MB-
231 breast cancer cell lines (with only ERǂ) no effects have been detected in the same 
conditions (Garcia-Roves et al., 2007). In addition it has been described , for prostrate cell 
lines which had the greatest levels of ERǃ and the lowest ERǂ/ERǃ ratio, that E2 treatment 
caused the up-regulation of antioxidant enzymes and UCPs with a look-up decrease in ROS 
production. These effects were reversed when the cells were treated with E2 in the presence 
of an ERǃ antagonist (Houstek et al., 1990). 
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ERǂ and ERǃ endowment can be of great importance in the establishment of oxidative stress 
in mitochondria, and may explain the opposite effects of estrogens found in different 
tissues. On the other hand, the presence of UCPs and their possible implication in the 
oxidative balance of breast cancer cell lines is notable and it should also be underscored that 
UCP expression is regulated, or sensible to, estrogen regulation and also to ERǂ/ERǃ ratio. 
For the above mentioned evidence, a better understanding of the molecular action of ERǂ 
and ERǃ, especially at mitochondrial level, is needed, as their role in ROS production could 
explain both the implication of estrogen in breast cancer development and its cancer 
protective role observed in other tissues. Additionally, a better understanding at this level 
could provide new dietary strategies for breast cancer prevention as well as new anticancer 
therapeutic procedures. 
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